Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study

INTRODUCTION: OPTIMIZE evaluated the efficacy, safety and treatment satisfaction of insulin glargine 300 U/mL once daily (Gla-300 OD) in people with type 1 diabetes mellitus (T1DM) previously uncontrolled on basal insulin twice daily (BID) as part of basal–bolus therapy. METHODS: OPTIMIZE was a 28-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, Chantal, Weisnagel, S. John, Stella, Peter, Bruhwyler, Jacques, Alexandre, Kathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995801/
https://www.ncbi.nlm.nih.gov/pubmed/31925722
http://dx.doi.org/10.1007/s13300-019-00749-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995801/
https://www.ncbi.nlm.nih.gov/pubmed/31925722
http://dx.doi.org/10.1007/s13300-019-00749-1

Ejemplares similares